30 percent sanctioned posts of doctors, paramedical staff in CGHS vacant: Parliamentary Panel

New Delhi: Around 30 per cent of the sanctioned strength of doctors and paramedical and administrative staff in all CGHS set-ups across the country are lying vacant, the parliamentary committee recommends the health ministry to fill up all vacant positions.

A parliamentary committee has flagged the issues of poor doctor-to-beneficiary ratio, long waiting times for patients in Central Government Health Scheme (CGHS) dispensaries and a decrease in the quality of patient care.

The Department-related Parliamentary Standing Committee on Health and Family Welfare in its 155th Report on the ‘Functioning of Central Government Health Scheme (CGHS)’ presented in Rajya Sabha noted an additional requirement of about 20 to 30 per cent of the sanctioned strength of doctors and paramedical and administrative staff, over and above the sanctioned strength, in all CGHS set-ups across the country.

Also Read:Private Hospitals Look Forward to Health Ministry Revision of CGHS Crucial Package Rates

The additional requirement for a junior health administrative assistant is around 70 per cent of the present sanctioned strength, the committee said, adding during the deliberation, the Union health ministry informed that a considerable percentage of the sanctioned strength of medical and administrative staff is also lying vacant.

“This leads to a poor doctor-to-beneficiary ratio, long waiting times for patients in CGHS dispensaries and a decrease in the quality of patient care,” it said.

Opening or operating CGHS centres without sufficient doctors and staff has no meaning and causes inconvenience to beneficiaries, the committee said, recommending the ministry to expedite the recruitment process and fill up all vacant positions.

The committee has also recommended the ministry to investigate the issues of delay in procurement and subsequent distribution of medicines.

It suggested bringing in necessary changes in the guidelines and simplifying the procedure for the local purchase of medicines to ensure an uninterrupted supply of medicines.

It also recommended that the ministry establishes a mechanism to ensure the continuous availability of basic or essential medicines at CGHS dispensaries so that the need for local purchase does not arise.

“The ministry should take necessary steps towards course correction, including making the required funds available for regular supply of medicines,” the panel said.

The committee stated that after visiting the medical officer at the wellness centre, the beneficiaries are issued medicines at the pharmacy counter.

If the medicines are available, they are issued right away. The medicines not readily available at the centre are indented and procured through an Authorized Local Chemist (ALC) within 48 hours.

It has come to notice that the medicines are often not procured promptly, causing inconvenience to the beneficiaries. In many cases, the bid or contract of the ALC is not renewed well in time and the dispensary is not in a position to supply the medicines, it highlighted.

It also suggested reducing the turnaround time to receive indented medicine to less than 24 hours.

“The ministry should make necessary course corrections to ensure that the indented medicines are available by the very next day morning,” the panel said.

In view of complaints regarding the quality of medicines disbursed at the pharmacy counter of the dispensary, the committee has recommended the ministry to establish a mechanism ensuring rigorous testing of medicines.

With respect to the payment or settlement of bills of empanelled hospitals, the ministry deposed before the committee that they had huge liabilities of pending bills.

On an average, bills amounting to Rs 10 to 12 crore per day are received by CGHS authorities across the country.

However, in the last financial year 2022-23, they cleared the bills to the tune of Rs 3100 crore, including the pendency carried forward from the year 2021-22.

In the financial year 2023-24, from April to July 2023, bills worth around Rs 1468 crore have been received by CGHS, out of which payment to the tune of approximately Rs 1672 crores (including the carried forward pending amount) has been made to the hospitals till August 24, 2023.

The committee observed that many bills due for payment are carried over to the next financial year owing to various reasons, which is affecting the credibility of CGHS.

“It is one of the major reasons for refusal of treatment to CGHS beneficiaries by some of the empanelled hospitals. The empanelled hospitals are in financial distress because of outstanding dues from CGHS,” it observed.

The panel recommended that the ministry establishes a mechanism for daily review of pending bills to ensure that the processing of bills gets smoother and disbursements are made seamlessly. The Ministry should fix a turnaround time for the settlement of bills, it said.

Powered by WPeMatico

Urokinase therapy improves diabetic foot ulcers healing and decreases CV events in diabetes patients

Urokinase therapy improves diabetic foot ulcer healing and decreases CV events in diabetes patients suggests a new study published in the BMJ Open Diabetes Research & Care.

Diabetic foot ulcer (DFU) is a disabling complication of diabetes mellitus. Here, we attempted to assess whether long-term intrafemoral artery infusion of low-dose urokinase therapy improved Diabetic foot ulcers and decreased cardiovascular events in patients with Diabetic foot ulcers. Diabetic foot ulcers were randomized to continuous intrafemoral thrombolysis or conventional therapy groups. The continuous intrafemoral thrombolysis group received continuous intrafemoral urokinase injection for 7 days, and conventional therapy just received wound debridement and dressing change. Then, a follow-up of average 6.5 years was performed. Results: Compared with conventional therapy, at the first 1 month of intervention stage, the ulcers achieved a significant improvement in continuous intrafemoral thrombolysis group including a complete closure (72.4% vs 17.5%), an improved ulcer (27.6% vs 25.8%), unchanged or impaired ulcer (0% vs 56.7%). During the 6.5-year follow-up, for the primary outcome of ulcer closure rate, continuous intrafemoral thrombolysis therapy obtained a better complete healing rate. For the secondary outcome of cardiovascular disease events, continuous intrafemoral thrombolysis therapy had a lower incidence of cardiovascular events. Importantly, intrafemoral thrombolysis therapy decreased the incidence of cardiovascular death (HR 0.42 Additionally, continuous intrafemoral thrombolysis therapy improved local skin oxygenation, peripheral neuropathy, and glycolipid metabolic profiles compared to conventional therapy group (p<0.05). Continuous intrafemoral thrombolysis therapy has a better therapeutic efficacy to improve Diabetic foot ulcers and decrease cardiovascular events.

Reference:

Tong J, Zhang J, Xiang L, Li S, Xu J, Zhu G, Dong J, Cheng Y, Ren H, Liu M, Yue L, Xiang G. Continuous intrafemoral artery infusion of urokinase improves diabetic foot ulcers healing and decreases cardiovascular events in a long-term follow-up study. BMJ Open Diabetes Res Care. 2024 Jan 12;12(1):e003414. doi: 10.1136/bmjdrc-2023-003414. PMID: 38216296.

Keywords:

Urokinase therapy, diabetic foot ulcers, diabetes and CV, diabetes patients, BMJ Open Diabetes Research & Care, Tong J, Zhang J, Xiang L, Li S, Xu J, Zhu G, Dong J, Cheng Y, Ren H, Liu M, Yue L, Xiang G, diabetic foot

Powered by WPeMatico

Black women in US murdered six times more often than White women between 1999 and 2020, finds state-level analysis

Black women in the U.S. were, on average, six times more likely to be murdered than their White peers over the past 20 years, according to a new analysis published in The Lancet.

Powered by WPeMatico

Researchers create machine learning-based classifier that could aid early diagnosis of psychosis

The onset of psychosis can be predicted before it occurs, using a machine-learning tool which can classify MRI brain scans into those who are healthy and those at risk of a psychotic episode.

Powered by WPeMatico

Repeat pre-eclampsia testing does not yield better outcomes for pregnant women, study finds

A single test to speed up diagnosis of a serious disease in pregnant women does not need to be repeated, new research has found.

Powered by WPeMatico

Evaluating the performance of AI-based large language models in radiation oncology

In a new study published in the journal AI in Precision Oncology, Nikhil Thaker, from Capital Health and Bayta Systems, and co-authors, evaluated the performance of various LLMs, including OpenAI’s GPT-3.5-turbo, GPT-4, GPT-4-turbo, Meta’s Llama-2 models, and Google’s PaLM-2-text-bison. The LLMs were given an exam including 300 questions, and the answers were compared to Radiation Oncology trainee performance.

Powered by WPeMatico

Study shows clinical benefit of a new way of treating advanced ER+ breast cancer

A research paper published today in The Lancet Oncology demonstrates that the drug enobosarm, a selective androgen receptor modulator that stimulates the male sex hormone receptor, has anti-tumor effects in estrogen receptor-positive breast cancer patients.

Powered by WPeMatico

Zydus Lifesciences bags USFDA nods for Dexamethasone Tablets USP, 0.5 mg, 0.75 mg, 1.5 mg, 4 mg and 6 mg and Dexamethasone Tablets USP, 2 mg

Ahmedabad: Zydus Lifesciences Limited has received final approvals from the United States Food and Drug Administration (USFDA) to manufacture and market Dexamethasone Tablets USP, 0.5 mg, 0.75 mg, 1.5 mg, 4 mg and 6 mg (USRLD: Decadron Tablets) and Dexamethasone Tablets USP, 2 mg
(USRLD: Dexamethasone Tablets).

Dexamethasone is used to treat a number of different conditions, such as inflammation
(swelling), severe allergies, adrenal problems, arthritis, asthma, blood or bone marrow
problems, kidney problems, skin conditions, and flare-ups of multiple sclerosis.

The products
will be manufactured at the group’s formulation manufacturing facility at Baddi, Himachal
Pradesh.

Dexamethasone Tablets USP, 0.5 mg, 0.75 mg, 1.5 mg, 4 mg and 6 mg had annual sales of
USD 22 mn and Dexamethasone Tablets USP, 2 mg has annual sales of USD 6 mn in the
United States (IQVIA Dec. Nov. 2023).

The group now has 386 approvals and has so far filed over 448* ANDAs since the
commencement of the filing process in FY 2003-04.

Read also: Zydus Lifesciences bags USFDA nod for Gabapentin Tablets (Once-Daily) for Postherpetic Neuraligia management

Medical Dialogues team had earlier reported that Zydus Lifesciences had received final approval from the USFDA for Clindamycin Phosphate Gel USP, 1% (USRLD: Cleocin T Gel, 1%).

Read also: Zydus bags USFDA nod for acne gel Clindamycin Phosphate

Formerly known as Cadila Healthcare Limited, Zydus Lifesciences Limited is an Indian multinational pharmaceutical company headquartered in Ahmedabad. The company is primarily engaged in the production of generic drugs. Cadila was founded in 1952 by Ramanbhai Patel.

Powered by WPeMatico

PGIMER Announces Round 3 Counselling Schedule For Sponsored Candidates Of INI CET January 2024

Chandigarh- The Postgraduate Institute of Medical Education and Research (PGIMER) Chandigarh has issued a notice announcing the upcoming 3rd physical counselling/seat allotment for candidates who applied under the sponsored category for MD/MS admission at PGIMER Chandigarh and qualified for the INI-CET (January 2024) conducted by All India Institute of Medical Sciences (AIIMS) New Delhi.

As per the notice, the third Physical Counselling/Seat Allotment is scheduled for Thursday, February 15th, 2024, at 11:00 AM in the APC Auditorium at PGIMER, Chandigarh. Candidates must be sited in the auditorium by 10:45 AM on February 15th, 2024. Later, the seats to be filled in the third counselling will be uploaded on the PGIMER website on the evening of 11 February 2024.

Candidates are instructed to submit one set of photocopies of certain original documents from their respective employers at the time of counselling. If the candidates fail to submit the documents they will not be considered for admission.

The documents that need to be submitted are mentioned below-

1 10th class certificate.

2 MBBS Degree.

3 Internship Certificate.

4 State Medical Council/National Medical Commission Registration Certificate.

5 Original Sponsorship Certificate.

6 No Objection Certificate (NOC).

Previously, PGIMER had announced the provisional seat allocations for the second counselling of sponsored candidates for the January 2024 session. According to the announcements, there were a total of 8 courses with a total of 30 vacant seats in the courses. Meanwhile, the second counselling session was scheduled for January 19, 2024, at 11:00 AM in the Bhargava Auditorium, PGIMER, Chandigarh.

To view the notice, click the link below-

Powered by WPeMatico

Goa doctor, 3 others create ruckus at restaurant; FIR registered

Panaji: A doctor and three others allegedly assaulted a fellow customer at a restaurant in Old Goa and created a ruckus there, police said on Thursday.

The incident took place around 11 pm on February 7, following which a case was registered against the four persons, they said.

The accused were identified as Dr Ajeya Mundhekar, Shubham Sawant, Swapnil Naik and Abraham Gaikwad, a police official said.

Also Read:Orthopedician booked after female patient attendant alleges sexual harassment

The accused doctor works as an interventional cardiologist in a private hospital near Panaji, he said.

“As per the probe conducted so far, the main accused in the case, Dr Mundhekar, started abusing his fellow customer and even broke the table of the restaurant located in Old Goa village,” the official added.

The police did not specify the motive behind the assault.

Based on a complaint filed by the victim, the police registered a case against the four accused on the charges of trespassing, provocation, damage to property, assault and wrongful restraint.

Powered by WPeMatico